Effects of meluadrine tartrate and ritodrine hydrochloride on oxytocin-induced uterine contraction, uterine arterial blood flow and maternal cardiovascular function in pregnant goats.
This study was designed to elucidate the effects of meluadrine tartrate on oxytocin-induced uterine contraction and maternal hemodynamics in unanesthetized, chronically instrumented pregnant goats. After the administration of meluadrine tartrate or ritodrine hydrochloride to pregnant goats, changes in heart rate (HR), arterial blood pressure (AOP), and arterial blood pH and gasses (P(O2) and P(CO2)) in the mother, as well as changes in intrauterine pressure (IUP) and uterine arterial blood flow (UBF), were measured. The escalating administration of meluadrine tartrate (0.03, 0.1, 0.3 and 1 micro g. kg(-)(1). min(-)(1)) or ritodrine hydrochloride (1, 3, 10 and 30 microg. kg(-)(1). min(-)(1)) to the maternal femoral vein caused a marked and similar inhibition in oxytocin-induced uterine contraction (a rise in IUP). By these escalating dosings, maternal HR was increased dose-dependently in both treatment groups; however, the degree of the HR increase in the meluadrine tartrate-treatment group was significantly less than that in the ritodrine hydrochloride-treatment group. Furthermore, the degree of the UBF decrease in the meluadrine tartrate-treatment group was significantly less than that in the ritodrine hydrochloride-treatment group. The present study suggests that meluadrine tartrate has a mild influence on the maternal cardiovascular function relative to the effects of ritodrine taking the potent efficacy on oxytocin-induced uterine contraction into account.
Matsuda
Yoshio
Y
Department of Obstetrics and Gynecology, Tokyo Women's Medical University, Tokyo, Japan. ymatsuda@obgy.twmu.ac.jp
Kouno
Satoshi
S
Sakamoto
Hiroshi
H
Ikenoue
Tsuyomu
T
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D002319:Cardiovascular System / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006041:Goats; D006339:Heart Rate / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D007262:Infusions, Intravenous; D010100:Oxygen / Q000097:blood; D010121:Oxytocin / Q000494:pharmacology; D011247:Pregnancy / Q000187:drug effects* / Q000502:physiology; D012039:Regional Blood Flow; D012312:Ritodrine / Q000494:pharmacology*; D013644:Tartrates / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D013997:Time Factors; D015149:Tocolytic Agents / Q000494:pharmacology*; D014590:Uterine Contraction / Q000187:drug effects*; D014599:Uterus / Q000098:blood supply* / Q000187:drug effects / Q000502:physiology
D000318:Adrenergic beta-Agonists; D013644:Tartrates; D015149:Tocolytic Agents; C422346:meluadrine tartrate; D002245:Carbon Dioxide; D010121:Oxytocin; D012312:Ritodrine; D010100:Oxygen